Edition:
India

Sientra Inc (SIEN.OQ)

SIEN.OQ on NASDAQ Stock Exchange Global Select Market

10.41USD
15 Feb 2019
Change (% chg)

$-0.10 (-0.95%)
Prev Close
$10.51
Open
$10.51
Day's High
$10.51
Day's Low
$10.25
Volume
178,014
Avg. Vol
137,240
52-wk High
$26.79
52-wk Low
$8.79

Latest Key Developments (Source: Significant Developments)

Sientra Reports Q2 Loss Per Share Of $0.73
Wednesday, 8 Aug 2018 

Aug 7 (Reuters) - Sientra Inc ::SIENTRA REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.73.Q2 EARNINGS PER SHARE VIEW $-0.69 -- THOMSON REUTERS I/B/E/S.Q2 SALES $17.6 MILLION VERSUS I/B/E/S VIEW $15.4 MILLION.PAUL LITTLE IS NEW CFO.APPOINT PATRICK WILLIAMS TO GENERAL MANAGER OF MIRADRY BUSINESS FROM CURRENT ROLE AS CFO.  Full Article

Sientra Receives FDA Approval Of PMA Supplement
Thursday, 19 Apr 2018 

April 18 (Reuters) - Sientra Inc ::SIENTRA RECEIVES FDA APPROVAL OF PMA SUPPLEMENT.SIENTRA INC - ADDITIONAL $10 MILLION OF EXISTING CREDIT FACILITY NOW ACCESSIBLE WITH FDA APPROVAL.SIENTRA INC - COMMERCIAL SALE OF U.S.-MANUFACTURED OPUS BRANDED BREAST IMPLANTS TO BEGIN IMMEDIATELY.  Full Article

Sientra Says Reached An Agreement-In-Principle With Staff Of Division Of Enforcement Of U.S. SEC
Tuesday, 27 Mar 2018 

March 26 (Reuters) - Sientra Inc ::SIENTRA INC - REACHED AN AGREEMENT-IN-PRINCIPLE WITH STAFF OF DIVISION OF ENFORCEMENT OF U.S. SECURITIES AND EXCHANGE COMMISSION - SEC FILING.SIENTRA - THERE IS NO MONETARY COMPONENT TO AGREEMENT-IN-PRINCIPLE, BUT IT WILL CONTAIN ORDER PROHIBITING FUTURE VIOLATIONS OF SECURITIES LAWS.SIENTRA INC - AGREEMENT-IN-PRINCIPLE TO SETTLE SEC'S INVESTIGATION RELATED TO CO'S FOLLOW-ON PUBLIC OFFERING THAT CLOSED ON SEPT. 23, 2015.SIENTRA - TO CO'S KNOWLEDGE, SEC DOES NOT INTEND TO CHARGE ANY OF CO'S CURRENT OFFICERS OR DIRECTORS RELATED TO INVESTIGATION.  Full Article

Sientra Provides Update On FDA Review Of U.S. Manufacturing Facility
Wednesday, 31 Jan 2018 

Jan 30 (Reuters) - Sientra Inc ::SIENTRA® PROVIDES UPDATE ON FDA REVIEW OF U.S. MANUFACTURING FACILITY.SIENTRA INC - ‍FDA GRANTED APPROVAL OF SITE-CHANGE PMA SUPPLEMENT FOR CONTRACT MANUFACTURER TO MANUFACTURE CO'S SILICONE GEL BREAST IMPLANTS​.  Full Article

Sientra Announces Preliminary Unaudited Q4 Revenue
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Sientra Inc ::SIENTRA ANNOUNCES PRELIMINARY UNAUDITED FOURTH QUARTER 2017 REVENUE.SEES Q4 2017 REVENUE ABOUT $11.4 MILLION.Q4 REVENUE VIEW $11.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Sientra Inc Files For Mixed Shelf Of Upto $150 Million
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Sientra Inc ::SIENTRA INC FILES FOR MIXED SHELF OF UPTO $150 MILLION - SEC FILING.  Full Article

Sientra posts qtrly loss of $0.74​ per share
Wednesday, 8 Nov 2017 

Nov 7 (Reuters) - Sientra Inc :Sientra reports third quarter 2017 financial results.Total net sales for Q3 2017 were $9.8 million, compared to total net sales of $6.5 million for same period in 2016​.Qtrly ‍basic and diluted net loss per share attributable to common stockholders $0.74​.Net cash and cash equivalents as of September 30, 2017 were $37.6 million compared to $55.5 million at end of Q2 2017​.  Full Article

UPDATE 1-SEC sues U.S. breast-implant company's ex-CEO after stock dive

Sept 19 The U.S. Securities and Exchange Commission on Wednesday sued the founder and former chief executive of Sientra Inc for fraudulently concealing problems with his company's breast and other implants as it was raising $61.4 million in a public stock offering.